Does Alder Biopharmaceuticals, Inc. (ALDR) Have Any Gas After Today’s Significant Decline?

March 21, 2018 - By Graig Alexander

The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) is a huge mover today! The stock decreased 15.07% or $2.05 during the last trading session, reaching $11.55. About 5.75 million shares traded or 255.78% up from the average. Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has declined 33.67% since March 22, 2017 and is downtrending. It has underperformed by 50.37% the S&P500.
The move comes after 8 months negative chart setup for the $783.61M company. It was reported on Mar, 21 by We have $10.97 PT which if reached, will make NASDAQ:ALDR worth $39.18M less.

Analysts await Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) to report earnings on April, 26. They expect $-1.26 earnings per share, up 36.68 % or $0.73 from last year’s $-1.99 per share. After $-0.80 actual earnings per share reported by Alder Biopharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 57.50 % negative EPS growth.

Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Ratings Coverage

Among 16 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 14 have Buy rating, 1 Sell and 1 Hold. Therefore 88% are positive. Alder Biopharmaceuticals had 34 analyst reports since August 6, 2015 according to SRatingsIntel. Piper Jaffray initiated the stock with “Overweight” rating in Monday, October 31 report. The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has “Buy” rating given on Monday, January 8 by RBC Capital Markets. The firm earned “Buy” rating on Thursday, February 8 by Canaccord Genuity. Needham maintained Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) on Tuesday, June 27 with “Buy” rating. The firm has “Hold” rating given on Wednesday, June 28 by Credit Suisse. The firm has “Buy” rating given on Thursday, June 29 by Aegis Capital. The firm has “Hold” rating given on Thursday, August 24 by Credit Suisse. The rating was maintained by Needham on Wednesday, November 8 with “Buy”. The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) earned “Overweight” rating by JP Morgan on Tuesday, September 13. The firm has “Outperform” rating by Wells Fargo given on Thursday, April 21.

Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. The company has market cap of $783.61 million. The companyÂ’s lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It currently has negative earnings. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.